News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

https://seekingalpha.com/article/4744437-immunitybio-forging-a-new-plan-after-recent-100-million-offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-inc-announces-pricing-public-offering-common-stock?field_nir_news_date_value[min]=

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-inc-announces-proposed-public-offering-common-stock

https://www.observertoday.com/news/top-stories/2024/11/town-hopeful-after-immunitybio-tour/

https://www.prnewswire.com/news-releases/immunitybio-and-ncartes-enter-collaboration-agreement-on-clinical-trial-data-fulfillment-302312171.html

https://wsw.com/webcast/jeff315/ibrx/1857828?mobile=True

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-anktivas-post-approval-enrollment-100th?field_nir_news_date_value[min]=

Q3 2024: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-third-quarter-2024-financial-results?field_nir_news_date_value[min]=

https://youtu.be/sOOvztLtZAQ

Bisschen Klatschpresse: https://www.boersennews.de/nachrichten/artikel/%22So-viel-Potenzial%22:-Diese-Aktie-kann-um-650-Prozent-steigen,-sagt-ein-Analyst/4594482/?utm_source=BoersennewsShare&utm_medium=App&utm_campaign=News

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma https://ir.immunitybio.com/news-releases/news-release-details/first-patients-dosed-phase-1-clinical-study-immunitybios-car-nk?field_nir_news_date_value[min]=

https://www.investing.com/news/company-news/ef-hutton-sets-stock-target-with-buy-rating-for-immunitybio-cites-cancer-therapy-93CH-3677443